Skip to main content

Table 1 Sequential treatment with Lm-ANXA2 and anti-PD-1 blockade antibody in genetically engineered KPC mice with spontaneous PDAC tumors resulted in greater tumor response

From: Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Treatment Group Interval decrease in tumor size before day 22 P value
Lm-ANXA2 2/11 (18%) Reference
Untreated 1/10 (10%) NS
Empty Lm 2/12 (17%) NS
Treatment Group Interval decrease in tumor size after day 22 P value
Lm-ANXA2 + anti-PD-1 8/10 (80%) Reference
Untreated 1/8 (13%) p = 0.015
Empty Lm 2/11 (18%) p = 0.009
  1. Percentages of mice with interval decreases in tumor size measured by ultrasound before and after Day 22 in untreated KPC mice (n = 10), KPC mice treated with Empty
  2. Lm (n = 12), and KPC mice treated with Lm-ANXA2 followed by anti-PD-1 antibodies (n = 12). ** p < 0.01; ***p < 0.001; ns, not significant. Comparison between percentages of mice with interval decreases in tumor size before vs. after Day 22 has a p value of 0.009